Sonus Pharmaceuticals Inc - Current report filing (8-K)
July 18 2008 - 2:02PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
July 16,
2008
SONUS PHARMACEUTICALS, INC.
(Exact name of Registrant as Specified in its Charter)
Delaware
|
|
000-21243
|
|
95-4343413
|
(State or other
jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No)
|
1522
217
th
Place S.E., Bothell, Washington 98021
(Address
of principal executive offices)
(425) 487-9500
(Registrants telephone number, including
area code)
Not
Applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
o
|
|
Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
|
|
|
|
o
|
|
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
o
|
|
Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
o
|
|
Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01.
Other
Events.
Sonus Pharmaceuticals, Inc., a Delaware
corporation (the
Company
), issued a press release on July 17,
2008, announcing that the Company received a notice from the NASDAQ Listing
Qualifications Panel (the
NASDAQ Panel
) on July 16, 2008
indicating that the NASDAQ Panel has determined to grant the Companys request
to continue the listing of its securities on The NASDAQ Global Market. The press release is attached as Exhibit 99.1
hereto.
Item 9.01.
Financial
Statements and Exhibits.
(d)
Exhibits.
Exhibit Number
|
|
Description
|
|
|
|
Exhibit 99.1
|
|
Press release issued by Sonus
Pharmaceuticals, Inc. on July 17, 2008.
|
2
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
|
SONUS PHARMACEUTICALS, INC.
|
|
|
|
|
Date: July 18, 2008
|
By:
|
/s/ Alan Fuhrman
|
|
|
Alan Fuhrman
|
|
|
Senior Vice President and Chief Financial Officer
|
3
Exhibit Index
Exhibit Number
|
|
Description
|
|
|
|
99.1
|
|
Press release issued by Sonus
Pharmaceuticals, Inc. on July 17, 2008.
|
4
Sonus (NASDAQ:SNUS)
Historical Stock Chart
From Apr 2024 to May 2024
Sonus (NASDAQ:SNUS)
Historical Stock Chart
From May 2023 to May 2024